Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City
Alberto Cedro‐Tanda, Laura Gómez-Romero, Guillermo de Anda‐Jáuregui, Dora Garnica-López, Yair Alfaro‐Mora, Sonia Sánchez-Xochipa, Eulices F. García-García, Alfredo Mendoza-Vargas, Emmanuel Frías-Jiménez, Bernardo Moreno, Abraham Campos‐Romero, José L. Moreno-Camacho, Jonathan Alcántar‐Fernández, Jesús Ortíz-Ramírez, Mariana Benitez-González, Roxana Trejo-González, Daniel Aguirre-Chavarría, Marcela Elizabeth Núñez-Martínez, Laura Uribe-Figueroa, Ofelia Angulo, Rosaura Ruiz, Alfredo Hidalgo‐Miranda, Luis A. Herrera
Abstract
Omicron is the most mutated SARS-CoV-2 variant-a factor that can affect transmissibility, disease severity, and immune evasiveness. Its genomic surveillance is important in cities with millions of inhabitants and an economic center, such as Mexico City. Results. From 16 November to 31 December 2021, we observed an increase of 88% in Omicron prevalence in Mexico City. We explored the R346K substitution, prevalent in 42% of Omicron variants, known to be associated with immune escape by monoclonal antibodies. In a phylogenetic analysis, we found several independent exchanges between Mexico and the world, and there was an event followed by local transmission that gave rise to most of the Omicron diversity in Mexico City. A haplotype analysis revealed that there was no association between haplotype and vaccination status. Among the 66% of patients who have been vaccinated, no reported comorbidities were associated with Omicron; the presence of odynophagia and the absence of dysgeusia were significant predictor symptoms for Omicron, and the RT-qPCR Ct values were lower for Omicron. Conclusions. Genomic surveillance is key to detecting the emergence and spread of SARS-CoV-2 variants in a timely manner, even weeks before the onset of an infection wave, and can inform public health decisions and detect the spread of any mutation that may affect therapeutic efficacy.